From cultivation to clinical translation: a critical review of ginger phytochemistry, antimicrobial mechanisms, bioavailability, and standardization
5 affiliations
- 1Department of Biomedical Sciences, Sunway University
- 2Science and Engineering Resources, Sunway College
- 3School of American Education (SAE), Sunway University
- 4Sunway Biofunctional Molecule Discovery Centre, Sunway University
- 5School of Dentistry and Medical Sciences, Charles Sturt University
Abstract
Ginger (Zingiber officinale Roscoe) is simultaneously a food, traditional medicine, and source of chemically diverse phenolic and volatile constituents. Its antimicrobial promise is supported by numerous in vitro studies, yet translation remains constrained by inconsistent botanical identification, extraction-dependent composition, non-comparable susceptibility assays, limited pharmacokinetic–pharmacodynamic integration, and a scarcity of controlled clinical evidence. This critical narrative review integrates botanical identity, genotype–environment and post-harvest effects, chemistry, analytical standardization, antimicrobial mechanisms, pathogen-specific evidence, human disposition, and formulation science. Rather than ranking cultivars on isolated measurements, the review treats cultivar, environment, maturity, processing, extraction, and analytical platform as interacting determinants of the final chemical phenotype. Evidence is organized mechanistically—membrane perturbation, biofilm and quorum-sensing interference, metabolic and enzymatic inhibition, oxidative stress, host-directed effects, and antimicrobial synergy—and then appraised by pathogen class. Gingerols and shogaols are rapidly transformed and extensively conjugated; therefore, nominal extract dose cannot be equated with systemic exposure to free parent compounds. HPTLC, HPLC/UPLC, LC–MS/MS, GC–MS, chemometrics, and validated reference materials are positioned as prerequisites for reproducible biological claims. Nanoformulations and ginger-derived vesicles may improve stability, localization, and exposure, but their safety, scalability, compositional definition, and comparative advantage require rigorous evaluation. Overall, ginger is best regarded as a platform for standardized antimicrobial adjuncts and food- or material-based applications, not as a clinically validated replacement for conventional anti-infective therapy. Future progress requires authenticated multicenter sample sets, harmonized assays, exposure-linked mechanistic studies, resistance-aware designs, and appropriately powered clinical trials.
Related
- Phytosomal Delivery of Natural Bioactives: Advancing Bioavailability, Targeted Drug Delivery, and Clinical Translation.
- Cold plasma technology as a novel antimicrobial platform: mechanisms, efficacy, and clinical translation: a systematic literature review
- Impact of Ayurvedic purification (Shodhana) on Mucuna pruriens for primary health care in Parkinson’s disease: phytochemical profile, bioavailability of L-DOPA, and comparative UPLC-MS/MS QTOF–Caco-2 analysis
- Multi-omics liquid biopsy identifies mitochondrial dysfunction in geographic atrophy and supports intraocular bioavailability of α-ketoglutarate
- Ethnomedicinal Uses, Phytochemistry and Bioactivities of Halophytes and Salt-Tolerant Plants with Potential Against Metabolic Syndrome: A Comprehensive Review
BibTeX
@article{jones2026from,
title = {{From cultivation to clinical translation: a critical review of ginger phytochemistry, antimicrobial mechanisms, bioavailability, and standardization}},
author = {Chris Izaak Jones and Haema Thevanayagam and Yee Mon Htet and Goh Bey Hing and Mohmad Farooq Shaikh and Kavitha Rajendran},
journal = {Beni-Suef University Journal of Basic and Applied Sciences},
year = {2026},
month = oct,
doi = {10.1186/s43088-026-00844-w},
url = {https://doi.org/10.1186/s43088-026-00844-w},
note = {CC BY},
}
RIS
TY - JOUR
TI - From cultivation to clinical translation: a critical review of ginger phytochemistry, antimicrobial mechanisms, bioavailability, and standardization
AU - Chris Izaak Jones
AU - Haema Thevanayagam
AU - Yee Mon Htet
AU - Goh Bey Hing
AU - Mohmad Farooq Shaikh
AU - Kavitha Rajendran
PY - 2026
DA - 2026/10/25
JO - Beni-Suef University Journal of Basic and Applied Sciences
DO - 10.1186/s43088-026-00844-w
UR - https://doi.org/10.1186/s43088-026-00844-w
AB - Ginger (Zingiber officinale Roscoe) is simultaneously a food, traditional medicine, and source of chemically diverse phenolic and volatile constituents. Its antimicrobial promise is supported by numerous in vitro studies, yet translation remains constrained by inconsistent botanical identification, extraction-dependent composition, non-comparable susceptibility assays, limited pharmacokinetic–pharmacodynamic integration, and a scarcity of controlled clinical evidence. This critical narrative review integrates botanical identity, genotype–environment and post-harvest effects, chemistry, analytical standardization, antimicrobial mechanisms, pathogen-specific evidence, human disposition, and formulation science. Rather than ranking cultivars on isolated measurements, the review treats cultivar, environment, maturity, processing, extraction, and analytical platform as interacting determinants of the final chemical phenotype. Evidence is organized mechanistically—membrane perturbation, biofilm and quorum-sensing interference, metabolic and enzymatic inhibition, oxidative stress, host-directed effects, and antimicrobial synergy—and then appraised by pathogen class. Gingerols and shogaols are rapidly transformed and extensively conjugated; therefore, nominal extract dose cannot be equated with systemic exposure to free parent compounds. HPTLC, HPLC/UPLC, LC–MS/MS, GC–MS, chemometrics, and validated reference materials are positioned as prerequisites for reproducible biological claims. Nanoformulations and ginger-derived vesicles may improve stability, localization, and exposure, but their safety, scalability, compositional definition, and comparative advantage require rigorous evaluation. Overall, ginger is best regarded as a platform for standardized antimicrobial adjuncts and food- or material-based applications, not as a clinically validated replacement for conventional anti-infective therapy. Future progress requires authenticated multicenter sample sets, harmonized assays, exposure-linked mechanistic studies, resistance-aware designs, and appropriately powered clinical trials.
SN - 2314-8543
SN - 2314-8535
ER -